These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Controversies about the use of psychoactive drugs in children and adolescents]. Sauceda-García JM Rev Med Inst Mex Seguro Soc; 2005; 43(5):369-71. PubMed ID: 16392190 [No Abstract] [Full Text] [Related]
4. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Bond GR; Garro AC; Gilbert DL Clin Toxicol (Phila); 2007; 45(2):182-5. PubMed ID: 17364639 [TBL] [Abstract][Full Text] [Related]
5. What is the significance of the new warnings about suicide risk with Strattera? Miller MC Harv Ment Health Lett; 2005 Dec; 22(6):8. PubMed ID: 16437773 [No Abstract] [Full Text] [Related]
6. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Eiland LS; Bell EA; Erramouspe J Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313 [TBL] [Abstract][Full Text] [Related]
7. Persistent camptocormia associated with atomoxetine in a child with attention-deficit/hyperactivity disorder. Bhattacharya A; Praharaj SK; Sinha VK J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):596-7. PubMed ID: 25469421 [No Abstract] [Full Text] [Related]
8. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742 [TBL] [Abstract][Full Text] [Related]
9. Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation. Tang CS; Chou WJ; Cheng AT J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):319-20. PubMed ID: 19519271 [No Abstract] [Full Text] [Related]
10. Increased blood pressure and atomoxetine. Dworkin N J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510. PubMed ID: 15908831 [No Abstract] [Full Text] [Related]
11. [Hemoperfusion with activated charcoal on valproic acid poisoning. A case report]. Sencion Martinez GL; Samillán K; Espinosa JL; Rodriguez Puyol D; Martinez Miguel P; Villa P Med Intensiva; 2015 Oct; 39(7):449-51. PubMed ID: 25583043 [No Abstract] [Full Text] [Related]
12. Atomoxetine use associated with onset of a motor tic. Ledbetter M J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):331-3. PubMed ID: 15910218 [TBL] [Abstract][Full Text] [Related]
13. Acute urinary retention associated with atomoxetine use. Desarkar P; Sinha VK Aust N Z J Psychiatry; 2006 Oct; 40(10):936. PubMed ID: 16959021 [No Abstract] [Full Text] [Related]
14. A case of severe akathisia with atomoxetine. Baweja R; Petrovic-Dovat L J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):426-7. PubMed ID: 23952192 [No Abstract] [Full Text] [Related]
15. Atomoxetine-induced hypomania-like symptoms in a preadolescent patient. Guney E; Uneri OS J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):530-1. PubMed ID: 24494808 [No Abstract] [Full Text] [Related]
18. [Therapy with psychotropic drugs in child and adolescent psychiatry. Possibilities and limitations]. du Bois R Dtsch Krankenpflegez; 1990 Apr; 43(4):266-9. PubMed ID: 2116274 [No Abstract] [Full Text] [Related]
19. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. Chen CY; Gerhard T; Winterstein AG J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):187-95. PubMed ID: 19364296 [TBL] [Abstract][Full Text] [Related]